Study Effect of Red Wine Consumption on Endothelial Progenitor Cells and Endothelial Function

NCT ID: NCT00755014

Last Updated: 2008-09-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-09-30
• Study Completion Date: 2008-07-31

Brief Summary

Light-to-moderate alcohol consumption has been associated with a reduction of cardiovascular events, and red wine seems to offer more benefits than any other type of alcoholic beverages. However, the relationship between red wine consumption and endothelial progenitor cells (EPCs) remains unclear. The investigators examine whether intake of red wine could enhance the number or functional capacity of circulating EPCs by upregulation of nitric oxide (NO) bioavailability.

Detailed Description

Moderate ethanol intake from any type of beverage has been shown to improve lipoprotein metabolism and lower cardiovascular mortality risk, but red wine, with its abundant antioxidant contents, seems to confer additional healthy benefits. Previous studies indicated that the beneficial effects of red wine are derived from increased endothelium-derived nitric oxide (NO), implying that enhanced NO bioavailability may mediate the cardiovascular protection provided by red wine.

Increasing evidence suggests that the injured endothelial monolayer is regenerated partly by circulating bone marrow derived-endothelial progenitor cells (EPCs), which accelerate reendothelialization and protect against the initiation and progression of atherosclerosis. Clinical studies demonstrated that the number of circulating EPCs predicts the occurrence of cardiovascular events and death from cardiovascular causes and may help to identify patients at increased cardiovascular risk. Although many epidemiologic studies have indicated that light-to-moderate consumption of red wine can reduce the incidence of CAD, the multifarious effects of red wine on circulating EPCs and endothelial function remain to be determined. Therefore, we design this study to test the hypothesis that intake of red wine can enhance the number and functional capacity of EPCs through increasing NO bioavailability.

Conditions

Endothelial Progenitor Cells Numbers; Endothelial Function (FMD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

2

Forty subjects are randomized to a group (n=20) that consumed red wine (100 ml) or a group (n=20) that consumed beer (250 ml) daily for 3 weeks

Group Type: EXPERIMENTAL

red wine

Intervention Type: OTHER

One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks

Interventions

red wine

One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks

Intervention Type: OTHER

Other Intervention Names

The red wine used is "Vin De Pays D'OC" (12.5% ethanol), a cabernet sauvignon from France; The beer used was Taiwan Beer (5% alcohol) from Taiwan.

Eligibility Criteria

Inclusion Criteria

• Forty young healthy subjects with no cardiovascular risk factors

Exclusion Criteria

• History of hypertension
• Diabetes mellitus
• Symptoms of CAD
• Smoking
• Chronic renal insufficiency (serum creatinine > 1.5 mg/dl)
• Inflammatory or liver diseases
• Regular alcohol consumption (drinking more than 20 g of ethanol per week)

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Yang Ming Chiao Tung University

OTHER

Sponsor Role: collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

Sponsor Role: lead

Responsible Party

Taipei Veterans General Hospital

Principal Investigators

Shing-Jong Lin, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Division of Cardiology, Taipei Veterans General Hospital

Po-Hsun Huang, MD

Role: STUDY_DIRECTOR

Division of Cardiology, Taipei Veterans General Hospital

Locations

Taipei Veterans Generla Hospital

Taipei, , Taiwan

Countries

Taiwan

Other Identifiers

VGHIRB No: 96-01-11A

Identifier Type: -

Identifier Source: org_study_id